Reshaping the Global Pharmaceutical Market Competitive Landscape: A Tripod of the US, Europe, and China — or China’s Innovation Accelerating to Overta

By:DengYue International Business Division

In the context of accelerated transformation in the global pharmaceutical industry, 2026 has become a critical window for observing changes in the competitive landscape. As a key bridge connecting Chinese innovation with global demand, cross-border pharmaceutical service platforms represented by Dengyue are deeply involved in this round of industrial restructuring. The traditional “tripod” pattern — dominated by the United States, closely followed by Europe, with China as a major market — is being redefined. Chinese innovative drug companies are transitioning from “followers” to “parallel runners or even partial leaders,” particularly excelling in the fields of obesity and oncology treatments.

Global Pharmaceutical Market Overview: Innovation Remains the Core Driver

According to IQVIA data, the global pharmaceutical market is projected to expand at a compound annual growth rate (CAGR) of 5%–8%, reaching approximately $2.6 trillion by 2030. Growth is primarily driven by two major areas: obesity therapies (GLP-1 class drugs) and oncology (antibody-drug conjugates [ADCs], bispecific antibodies, and related innovative modalities).

The United States remains the world’s largest single market, accounting for about 50% of branded drug sales and more than half of global pharmaceutical profits. Its advantages lie in high pricing, rapid FDA approvals, and the most favorable commercialization environment, allowing new drugs to launch first in the US and achieve high penetration. The European market is mature but faces fragmented regulation, lower pricing, and budget pressures, resulting in relatively slower adoption of innovative drugs. As the second-largest market, China has grown the fastest in recent years. Since 2020, its medicine use volume index has consistently led, and by 2030 it is expected to nearly double compared to 2020 levels.

Comparison of Innovative Drug Adoption Speed: Developed Markets Lead, but China Is Accelerating

Clear differences exist in adoption between the US and Europe.

In the US, innovative drugs penetrate rapidly after launch:

sales within 6 months can reach about 43% of the 18-month peak, and 77% by 12 months. Germany, the fastest market in Europe, achieves 68% uptake at 6 months and 93% at 12 months, while France, the UK, and others lag significantly. In China, domestic adoption of innovative drugs starts more slowly (about 23% at 6 months and 59% at 12 months). However, with accelerated National Reimbursement Drug List (NRDL) negotiations and accumulation of real-world evidence, post-launch penetration is speeding up.

Developed markets (especially the US) still hold significant advantages in commercialization execution, physician education, and payment systems, enabling shorter timelines from approval to widespread use. Europe, however, faces budgetary pressures from aging populations and health technology assessment (HTA) barriers, which can delay market entry or limit coverage for certain innovative therapies.

Chinese Domestic Market:

Although starting later, regulatory reforms have significantly shortened approval timelines (IND review approximately 30 working days). Through priority review and rapid NRDL inclusion, innovative drugs are quickly incorporated. In 2025, China approved a record 76 innovative drugs. Domestic clinical trial volume has approached US levels, with patient recruitment speeds often 2–5 times faster than in the US and Europe. This provides Chinese companies with a “speed advantage,” though domestic pricing pressures and volume-based procurement (VBP) mechanisms continue to test the sustainability of commercialization.Strong Momentum in Chinese Innovation Going Global: From Pipeline Export to Worldwide Recognition

Chinese innovative drug pipelines now account for approximately 20%–30% of global innovative drug development, with particular strength in ADCs, bispecific antibodies, CAR-T therapies, and GLP-1 agents. In 2025, the value of Chinese out-licensing deals reached a record high, with some data showing up to $137.7 billion (including milestones). Momentum has continued strongly into the first half of 2026, with multiple high-value transactions involving multinational giants such as AstraZeneca and AbbVie.

Key driving factors include:

● R&D Speed and Cost Advantages: The cycle from early discovery to IND in China is 50%–70% faster than the global average. Clinical trial execution is highly efficient, and development costs are significantly lower than in the US and Europe.

● Modal Leadership: China leads globally in next-generation antibody engineering pipelines (such as ADCs and multispecific antibodies), holding a substantial share of the world’s ADC pipeline.

● Globalization Strategy: From early licensing to global rights deals, Chinese assets are filling pipeline gaps for multinationals facing patent cliffs. Transactions in obesity and oncology are particularly active, with some Chinese GLP-1 assets gaining favor from international big pharma.

● Platform Capabilities: Indigenous innovations such as AI-assisted discovery and sustained-release technologies are gaining global recognition.

Meanwhile, China’s export structure continues to optimize, with a rising proportion of high-value innovative drugs and high-performance medical devices. Pharmaceutical exports exceeded $100 billion in the first 11 months of 2025.

Tripod Structure or China’s Accelerated Overtake?

The current landscape still exhibits “tripod” characteristics: the US maintains its lead through commercialization and pricing advantages; Europe retains competitiveness in mature technologies and certain fields; and China demonstrates catching-up momentum in innovation supply speed and early pipeline generation. China’s clinical trial initiation volume has approached that of the US, accounting for nearly 30%–39% globally, while the number of new drug approvals has surpassed Europe in recent years and is closing in on the US.

However, “overtake” does not mean comprehensive replacement:

● Remaining Gaps: The US leads in fundamental scientific breakthroughs, venture capital (over 60% of global biotech VC share), and high-end commercialization execution. Chinese innovative drugs still need time to accumulate real-world penetration and long-term efficacy data in premium global markets.

● Geopolitical and Regulatory Variables: Policies such as the US BIOSECURE Act may affect Sino-US cooperation but are also prompting China’s ecosystem to become more self-sufficient. If Europe fails to address regulatory fragmentation and insufficient investment, it risks further marginalization.

● Complementary Rather Than Zero-Sum: Multinationals supplement their pipelines by licensing Chinese assets, while Chinese companies leverage international partners to accelerate global registration and sales — forming a new model of “Chinese speed + global execution.”

Looking ahead to 2026 and beyond, obesity and oncology drugs will continue to drive growth. If Chinese innovation achieves more “first-in-class” or “best-in-class” breakthroughs in out-licensed products and successfully balances domestic pricing with sustainable innovation, its global influence will expand further. The high adoption speed in developed markets will remain key to monetizing innovation, while China is reshaping the competitive landscape from the supply side.

Conclusion

The global pharmaceutical market is shifting from a structure of “US dominance, Europe following, China following” toward a more dynamic competitive ecosystem. China’s accelerated globalization of innovation is not about simple replacement but rather bringing more choices and greater accessibility to patients worldwide. Cross-border pharmaceutical platforms such as Hong Kong-based Dengyue are playing an increasingly important role by efficiently connecting Chinese biopharmaceutical innovation with global demand. In this reshaping process, cooperation and competition coexist. The companies and ecosystems that best balance speed, innovation quality, and commercial sustainability will secure the most advantageous positions.

(Data sourced from public reports by IQVIA, Evaluate, and industry analyses; specific figures should be verified against the latest official disclosures.)